We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

New Insights Into How Ovarian Cancer Grows and Evolves


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Insights Into How Ovarian Cancer Grows and Evolves"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

In a paper published in the journal Cancer Research, Associate Professor Levi Waldron, post-doctoral fellow Ludwig Geistlinger, and colleagues at the Institute for Implementation Science in Population Health (ISPH) at the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) provide new insights into how ovarian cancer grows and evolves within a person.

The paper, “Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma” [1] is of basic scientific interest for its methodology and insights into the decades-long process of tumorigenesis, and of practical interest for the implications these insights have on the viability of subtype-targeted therapies. More than 20,000 women receive a new diagnosis of ovarian cancer each year in the United States, and approximately 14,000 die each year.

“Understanding how a heterogeneous tumor evolves prior to diagnosis is difficult because we can’t directly observe that evolution,” says Professor Waldron. “But by observing tumors identified at different stages of that evolution, and through detailed investigation of tumor genomics and heterogeneity, we can still learn something about it. The key thing we wanted to know was whether a tumor starts as a certain subtype and stays that way, or evolves, changes, and even multiplies subtypes over time. If subtypes can evolve and multiply within one tumor, then subtype-specific therapies are unlikely to help.”

To answer these questions, the team developed a new method of inferring the existence of heterogeneous subtypes from complementary types of genomic data, published separately in the Journal of Clinical Oncology – Clinical Cancer Informatics [2], and teamed up with researchers from the University of Minnesota who leveraged new technology to sequence the RNA of single cells.

“We used complementary but completely different approaches to approach the same question – one using more traditional approach using DNA and RNA sequencing of hundreds of bulk tumors, and the other using new single-cell sequencing methods for a few tumors,” Waldron elaborates, “Seeing a consistent picture from both approaches really strengthened confidence in results coming from two novel approaches.”

A surprising outcome of the research is a dismissal of the idea of discrete transcriptome subtypes for this cancer, and replacement by a model of continuous tumor development that includes mixtures of subclones, accumulation of mutations, infiltration of immune and stromal cells in proportions correlated with tumor stage and tissue of origin, and evolution between properties previously associated with discrete subtypes.

“Unfortunately, previous ideas of discrete subtypes were overly simplistic and unlikely to progress our understanding, prevention, or treatment of this disease,” says Waldron. “Fortunately, with the clearer picture emerging of tumor heterogeneity, and the rapid development of technologies to help understand it, we are well-positioned to make progress.”

The project involved a primary collaboration with the University of Minnesota where single-cell RNA sequencing was performed, and with the Dana-Farber Cancer Center, University of Arkansas for Medical Sciences, Novartis Institutes for Biomedical Research, Memorial Sloan Kettering Cancer Center, and Roswell Park Comprehensive Cancer Center. CUNY SPH post-doc Sehyun Oh, and MPH alumni Marcel Ramos and Lucas Schiffer were also involved in the research.

References

[1] Geistlinger L, et al. (2020). Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma. Cancer Res. DOI: https://cancerres.aacrjournals.org/content/early/2020/08/01/0008-5472.CAN-20-0521

[2] Oh S, Geistlinger L, et al. (2020). Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data. JCO Clinical Cancer Informatics. DOI: 10.1200/CCI.19.00130 

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement